ERJ Open Research最新文献

{"title":"ERS Congress 2025: highlights from the Paediatrics Assembly.","authors":"Deepa Patel, Shahriyar Shahbazi Khamas, Pia Maier, Refika Ersu, Alexander Moeller, Susanne J H Vijverberg","doi":"10.1183/23120541.00038-2026","DOIUrl":"10.1183/23120541.00038-2026","url":null,"abstract":"<p><p>#ERSCongress 2025: surge in youth #vaping, new evidence on exposome-driven risks, advances in rare paediatric lung diseases. Strong global collaboration remains essential to support low-resource settings and reduce growing respiratory #healthinequities. https://bit.ly/4tv2mrz.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A protocol for validation of novel artificial intelligence-based framework for dyspnoea investigation with cardiopulmonary exercise testing.","authors":"Abed A Hijleh, Danilo C Berton, Matthew D James, Reginald M Smyth, Sandra G Vincent, Madison Coyle, Devin Phillips, Amany F Elbehairy, Nicolle J Domnik, Denis E O'Donnell, J Alberto Neder","doi":"10.1183/23120541.00269-2026","DOIUrl":"10.1183/23120541.00269-2026","url":null,"abstract":"<p><strong>Background: </strong>Exertional dyspnoea largely represents the sensory translation of an ever-growing dynamic mismatch between ventilatory demand and capacity as exercise intensifies. This fundamental tenet, however, has not been formally incorporated into data display and clinical interpretation of incremental cardiopulmonary exercise testing (CPET). The objectives of the present study were to validate a novel framework (Dynamic Assessment of Dyspnoea and Ventilation on Exercise (DyVe-X)) to quantify the severity of exertional dyspnoea while exposing its mechanical-ventilatory underpinnings across progressively higher exercise intensities in subjects showing varied pre-test likelihood of abnormality.</p><p><strong>Methods: </strong>Incremental CPET data from three large cohorts of tobacco-exposed subjects: smokers and ex-smokers at risk for, or at different stages of, COPD (n=1161). Based on recently published normative data, a homonymous software (DyVe-X 1.0.0 Kingston, ON, Canada) uses an algorithm based on artificial intelligence techniques to establish the burden of 1) exertional dyspnoea <i>versus</i> work rate and ventilation, 2) excessive breathing (low submaximal ventilatory reserve, high dyspnoea-work rate but preserved dyspnoea-ventilation), and 3) constrained breathing (reduced inspiratory reserve, high dyspnoea-work rate and dyspnoea-ventilation). We hypothesise that categories of progressive mechanical-ventilatory abnormalities, based on DyVe-X, would exhibit progressively worse physiological and sensory CPET outcomes. Using the current key criterion to indicate ventilatory limitation to exercise (peak breathing reserve ≤15%) as the comparator, we anticipate a superior performance of DyVe-X in exposing dyspnoea-generating mechanical-ventilatory abnormalities across cohorts.</p><p><strong>Implications: </strong>This study may validate an original framework for investigating dyspnoea using CPET, characterised by continuous assessment of symptom intensity and time course, in light of the rate of dynamic depletion of mechanical-ventilatory reserves.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological biomarkers predict pulmonary and nodal, but not cardiac positron emission tomography-assessed sarcoidosis activity.","authors":"Roberto Colli, Yuan Tian, Melina Stuessi-Helbling, Anna Himmelmann-Wildschuetz, Christian Clarenbach, Ronny Ralf Buechel, Sonja Katz, Lukas Frischknecht, Jakob Nilsson","doi":"10.1183/23120541.01414-2025","DOIUrl":"10.1183/23120541.01414-2025","url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a systemic granulomatous disease with highly variable clinical manifestations and organ involvement. Symptoms are often unspecific or absent and may not reflect true inflammatory burden, increasing the risk of delayed detection of organ damage. Reliable assessment of disease activity is therefore essential for treatment guidance. We aimed to investigate the correlation and predictive performance of circulating biomarkers with systemic inflammatory activity as assessed by ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography-computed tomography (PET-CT), exploring whether a biomarker-based approach could substitute more resource-intensive imaging.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study including 180 patients with systemic sarcoidosis who underwent paired ¹⁸F-FDG PET-CT and blood sampling (n=770). Systemic biomarkers including tumour necrosis factor-α (TNF-α), soluble interleukin-2 receptor (sIL-2R), neopterin, angiotensin-converting enzyme (ACE) activity, C-reactive protein (CRP), calciuria and lymphocytopenia were assessed for their association with PET-based inflammatory activity. Variance and correlation analyses as well as receiver operating characteristic curves were used to evaluate diagnostic performance.</p><p><strong>Results: </strong>TNF-α, sIL-2R and neopterin consistently showed significant correlation with PET activity already for moderate inflammatory activity (activity-quartile 2-3 <i>versus</i> inactive: p<0.001), with TNF-α showing the best predictive ability, though overall degree of correlation remained moderate (Pearson's r<0.5; area under the curve: 0.63-0.68). Traditional biomarkers such as ACE activity and CRP only showed significant differences at the highest quartile of PET activity (activity-quartile 4 <i>versus</i> inactive p<0.001 and p=0.005, respectively). While biomarker correlations were evident for pulmonary and nodal inflammation, weak to no association was found for PET-assessed cardiac activity.</p><p><strong>Conclusion: </strong>Immunological biomarkers such as TNF-α, sIL-2R and neopterin outperform traditional markers such as CRP and ACE activity, and should be considered in the assessment of systemic sarcoidosis activity at diagnosis and follow-up. Since no biomarker was able to predict cardiac inflammatory activity, imaging techniques such as magnetic resonance imaging and ¹⁸F-FDG PET remain central for diagnosis and exclusion of cardiac sarcoidosis.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond random variation: Monte Carlo analysis and predictability of COPD exacerbations.","authors":"Surya P Bhatt, Sandeep Bodduluri, Abdulhakim Tlimat, Arie Nakhmani, Mohsen Sadatsafavi","doi":"10.1183/23120541.01516-2025","DOIUrl":"10.1183/23120541.01516-2025","url":null,"abstract":"<p><p><b>Both moderate and severe exacerbations of COPD follow patient-specific, predictable patterns rather than occurring as random events of chance</b> https://bit.ly/4d6TkMS.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary function in young childhood cancer survivors: results from a prospective multicentre cohort.","authors":"Maša Žarković, Christina Schindera, Nicolas Waespe, Daniel Trachsel, Anne Mornand, Marc Ansari, Philipp Latzin, Claudia E Kuehni","doi":"10.1183/23120541.00500-2026","DOIUrl":"10.1183/23120541.00500-2026","url":null,"abstract":"<p><strong>Background: </strong>Childhood cancer survivors (CCSs) are at risk of pulmonary late effects, but post-treatment lung function remains understudied. Current guidelines recommend screening only for symptomatic survivors treated with lung-damaging treatments. We evaluated pulmonary function, risk factors and respiratory symptoms in a representative paediatric CCS cohort, including those with standard treatments.</p><p><strong>Methods: </strong>In this prospective multicentre study, we included CCSs aged 6-21 years, stratified as high-risk (thoracic radiotherapy/surgery, busulfan/bleomycin/nitrosourea chemotherapy and haematopoietic stem cell transplantation (HSCT)) or standard-risk (other systemic treatment). Pulmonary function was assessed <i>via</i> spirometry (forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC)), body plethysmography (total lung capacity (TLC)) and diffusing capacity for carbon monoxide (<i>D</i> _LCO), expressed as z-scores using Global Lung Initiative references. We assessed respiratory symptoms <i>via</i> questionnaires and analysed treatment associations with pulmonary function using multivariable linear regression.</p><p><strong>Results: </strong>With a response rate of 90%, 251 CCSs participated (median 7 years post-diagnosis). Mean z-scores for FEV₁, FVC, TLC and <i>D</i> _LCO were lower in high-risk (-0.70, 95% confidence interval -0.96 to -0.43; -0.91, -1.16 to -0.66; -0.54, -0.78 to -0.31; and -0.17, -0.55 to 0.22, respectively) than standard-risk survivors (-0.10, -0.26 to 0.06; -0.22, -0.37 to -0.06; -0.17, -0.33 to -0.01; and 0.32, 0.15 to 0.49). Thoracic surgery and nitrosoureas were associated with lower TLC (-0.53 and -1.37), HSCT with reduced FEV₁ and FVC (-0.80 and -0.84) and thoracic radiotherapy with lower <i>D</i> _LCO (-0.63). Respiratory symptoms were reported by 32%, but 64% of those with impaired lung function were asymptomatic.</p><p><strong>Conclusion: </strong>Pulmonary function was mostly normal in standard-risk CCSs, whereas high-risk survivors showed mild reductions, often asymptomatic. These findings support targeted surveillance based on treatment exposure rather than symptoms to guide long-term care.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13548452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148905661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across Europe.","authors":"Dace Matīsa, Aruna T Bansal, Saša Rink, Anna Freeman, Betty Frankemölle, Mehar Singh, Jacob K Sont, Apostolos Bossios, Ben Ainsworth, Michael Hyland, Rekha Chaudhuri, Florin Mihaltan, Antonio Spanevello, Enrico Heffler, Ian Adcock, Martina Zappa, Giorgio Walter Canonica, Guy Brusselle, Arnaud Bourdin, Giulia Anna Maria Luigia Costanzo, Ildiko Horvath, Dóra Lúðvíksdóttir, Stefania Principe, Peter Kopač, Cláudia Chaves Loureiro, Arne Egesten, Stephanie Korn, Konstantinos Samitas, Marcus Butler, Joerg Leuppi, Edin Jusufovic, Felix Wantke, Shane Hanon, Fabienne Jaun, Virginija Kalinauskaite-Zukauske, Sanja Dimic-Janjic, Graham Roberts, Sanja Hromis, Branislava Milenkovic, Judit Varkonyi-Sepp, Ozlem Goksel, Ana Margarida Pereira, Ratko Djukanovic, Angela Rizzi, Marco Caminati, Ruihua Hou, Anamarija Štajduhar, Dóra Paróczai, Luisa Brussino, Liam G Heaney, Hans Michael Haitchi, Matteo Bonnini, Kristina Bieksiene, Ebru Damadoglu, Valentyna Yasinska, Bilun Gemicioglu, Sanja Popović Grle, Anneke Ten Brinke, Zsuzsanna Csoma, Iveta Kroiča, Piotr Kuna, Celeste Porsbjerg, Hilary Hodge, Florence Schleich, Sabina Skrgat, Ramesh J Kurukulaaratchy","doi":"10.1183/23120541.00157-2026","DOIUrl":"10.1183/23120541.00157-2026","url":null,"abstract":"<p><strong>Background: </strong>Multimorbidity refers to the presence of multiple coexisting conditions, but is often underappreciated in the context of severe asthma (SA) management. We sought to identify differences in approaches to multimorbidity management in SA, variability in access to multidisciplinary team (MDT) resources, and whether physician perspectives on multimorbidity differ between SA specialists and general respiratory physicians.</p><p><strong>Methods: </strong>The Severe Heterogeneous Asthma Registry, Patient-centred (SHARP) Clinical Research Collaboration circulated an online physician survey <i>via</i> European national respiratory societies to assess 1) available resources to address multimorbidity and 2) physician perspectives on multimorbidity in SA.</p><p><strong>Results: </strong>495 responses from 25 European countries included 48% SA specialists and 52% general respiratory physicians. SA specialists had more experience with SA patients (20% were seeing >60 patients per month) compared to general respiratory physicians. SA specialists had greater access to multidisciplinary care - including better access to MDTs, allied health professionals and referrals to external specialists, and therefore more routinely assessed comorbidities and considered them greater influences on their practice. They also considered multimorbidity to a greater degree and rated its impact on their patients' asthma outcomes (and general health outcomes) as more substantial.</p><p><strong>Conclusions: </strong>Alongside more experience of treating SA, SA specialists have increased awareness of multimorbidity and better resources to manage it. However, access to MDTs remains a significant gap for both SA specialists and general respiratory physicians. Furthermore, both groups identified a high need for further education and training about multimorbidity. These findings highlight key areas for improvement in clinical practice, resources and training.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient, family member and healthcare professionals' experiences of physiotherapy airway clearance techniques during hospital admission: a scoping review.","authors":"Kirsty Jerrard, Rhian Dowding, Brenda O'Neill, Judy M Bradley, Bronwen Connolly","doi":"10.1183/23120541.00140-2026","DOIUrl":"10.1183/23120541.00140-2026","url":null,"abstract":"<p><strong>Introduction: </strong>Effective secretion management is crucial for hospitalised patients with retained secretions due to critical illness, chronic respiratory disease or infection. Airway clearance techniques (ACT), primarily physiotherapist-delivered and advocated in guidelines, support secretion removal. However, limited knowledge exists regarding the experiences of patients, family members and healthcare professionals involved in ACT. The aim of the present study was to explore the experiences of patients, family members and healthcare professionals of ACT in hospital settings.</p><p><strong>Methods: </strong>Following JBI (formerly Joanna Briggs Institute) recommendations and the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews Checklist, searches were conducted in CINAHL Complete, EMBASE, MEDLINE ALL, PsycINFO and ProQuest Dissertations & Theses Global, from inception to 17 November 2025. Qualitative studies involving patients (≥16 years) receiving ACT, family members involved or healthcare professionals delivering ACT in the hospital setting were eligible. Screening and data charting were performed independently and in duplicate. Findings were synthesised descriptively and narratively.</p><p><strong>Results: </strong>Of 10 370 records identified, 11 studies met the inclusion criteria. Six studies reported primary themes related to ACT, while relevant source text from the remaining five studies was extracted and integrated into the narrative synthesis. Populations included healthcare professionals (physiotherapists, nurses, intensivists, internal medicine specialists; n=293) and patients (n=80). No studies included family members. Settings were predominantly intensive care units (ICU) (n=9), with two studies spanning ICU and ward settings. Four overarching themes emerged: three shared by patients and healthcare professionals (Knowledge, resources, and skills; Decision-making process; Perceived effects and outcomes), and one unique to healthcare professionals (Organisational factors).</p><p><strong>Conclusions: </strong>Current evidence on experiences of ACT is dominated by physiotherapists and ICU settings, with no studies capturing family perspectives and limited patient or wider multidisciplinary input across broader hospital contexts. More inclusive, stakeholder-informed research is needed to fully understand ACT use, impact and burden in clinical practice.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase III AIRTIVITY study design: verducatib (BI 1291583) in people with bronchiectasis.","authors":"James D Chalmers, Michal Shteinberg, Sanjay H Chotirmall, Wiebke Sauter, Patrick A Flume, Raksha Jain, Kozo Morimoto, Anne E O'Donnell, Felix C Ringshausen, Henrik Watz, Jin-Fu Xu, Johanna Rauch, Anastasia Eleftheraki, Annemarie T Engel, Anne B Chang, Kim G Nielsen, Giselle Benitez, Abhya Gupta, Marcus A Mall, Pamela J McShane","doi":"10.1183/23120541.01068-2025","DOIUrl":"https://doi.org/10.1183/23120541.01068-2025","url":null,"abstract":"<p><p>There is an unmet need for therapies targeting chronic neutrophilic inflammation in bronchiectasis. In the phase II, dose-finding AIRLEAF study, the dipeptidyl peptidase 1 (cathepsin C) inhibitor verducatib (BI 1291583) reduced the pulmonary exacerbation risk in people with bronchiectasis and demonstrated a similar safety profile to placebo; these results support the investigation of verducatib in a phase III study. Here, we describe the design of the randomised, placebo-controlled phase III AIRTIVITY study (ClinicalTrials.gov identifier NCT06872892), assessing the efficacy, safety and tolerability of verducatib in people with bronchiectasis. In AIRTIVITY, approximately 1680 adults and 75 adolescents (aged 12-<18 years) with bronchiectasis with a broad range of aetiologies are randomised 2:1 to receive oral verducatib 2.5 mg or placebo for at least 52 weeks and up to 76 weeks. Unlike previous studies of bronchiectasis, people with cystic fibrosis bronchiectasis are included. The primary objective is to demonstrate the superiority of verducatib compared with placebo on the annualised rate of pulmonary exacerbations up to 76 weeks. The main secondary objective is to demonstrate a reduction in lung function decline, an improvement in respiratory symptoms, a prolongation in time to first pulmonary exacerbation and a reduction in annualised rate of severe pulmonary exacerbations for verducatib <i>versus</i> placebo. All pulmonary exacerbations are adjudicated. If the efficacy of verducatib is demonstrated and there is a favourable benefit-risk ratio, the AIRTIVITY results will provide confirmatory evidence for the use of verducatib 2.5 mg in a large and broad bronchiectasis population, independent of underlying aetiology.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical comorbidity phenotypes in COPD and their biomarker signatures.","authors":"Line Egerod, Diana J Leeming, Morten A Karsdal, Julie C Yates, Jannie M B Sand, Cecilie L Bager","doi":"10.1183/23120541.00127-2026","DOIUrl":"10.1183/23120541.00127-2026","url":null,"abstract":"<p><p><b>Biomarkers of inflammation, coagulation and fibroblast activity differ across COPD comorbidity phenotypes, revealing biologically plausible signatures and suggesting potential endotypes that reflect subclinical disease processes</b> https://bit.ly/49t5nkW.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eosinophil biology in COPD: from scientific insight to clinical treatment action.","authors":"Steven P Cass, Mona Bafadhel","doi":"10.1183/23120541.01301-2025","DOIUrl":"10.1183/23120541.01301-2025","url":null,"abstract":"<p><p>COPD is a common lung disease that causes significant global morbidity. Strikingly, elevated blood and/or airway eosinophil levels are observed in up to 40% of COPD patients. These innate immune cells are clinically associated with increased exacerbation frequency and risk. Eosinophils are key in COPD symptom management and a drive to uncover their related immunopathology is critical to our understanding of disease progression. Recent biologic treatments targeting eosinophils have had success in reducing symptoms in eosinophilic COPD patients. However, the underlying pathways that lead to these improvements is incompletely understood. Given eosinophils are important in pathogen clearance, mucus viscosity, barrier integrity and tissue remodelling, any disease modifying treatments will have several proposed mechanisms. In this narrative review, we summarise the developmental, recruitment, activation and related pathology of eosinophils in the context of eosinophil-depleting treatments to elucidate treatment efficacy. Furthermore, we highlight potential future biological pathways for therapeutics aimed at specific eosinophil mechanisms.</p>","PeriodicalId":11739,"journal":{"name":"ERJ Open Research","volume":"12 5","pages":""},"PeriodicalIF":4.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13531299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}